Haemonetics Corporation disclosure: a group affiliated with North Peak Capital reports beneficial ownership of 2,370,495 shares, equal to 5.1% of common stock based on 46,471,350 shares outstanding as of January 30, 2026.
The filing is a joint Schedule 13G showing that North Peak Capital Management, LLC (investment manager) and related entities and individuals (including North Peak Capital GP, LLC; North Peak Funds; Jeremy S. Kahan; Michael K. Kahan) may be deemed to beneficially own the disclosed shares, with 1,882,037 shares (4.0%) attributable to North Peak Capital GP and the Kahan reporting persons. The filings include specific per‑entity holdings and state the group disclaims direct beneficial ownership beyond the amounts shown.
Positive
None.
Negative
None.
Insights
North Peak group reports a modest passive stake in Haemonetics.
The filing lists 2,370,495 shares (5.1%) held across North Peak funds and accounts, calculated from 46,471,350 shares outstanding as of January 30, 2026. The statement is submitted on a joint basis by management, GP and two co‑managers.
Ownership is reported as shared voting/dispositive power for key entries; the disclosures and joint filing language suggest an investment manager/general partner relationship rather than an operational control intent. Subsequent Section 13 filings would show any change in status.
Filing clarifies holdings by multiple North Peak entities and individuals.
The cover pages break down holdings: examples include North Peak Capital Partners II with 993,566 shares (2.1%), Alpha Fund with 651,061 shares (1.4%), and Ultra Fund with 102,056 shares (0.2%). The filing ties percentages to the January 30, 2026 outstanding share count.
Because the filing uses shared power figures and contains disclaimers, the economic/ voting influence depends on fund arrangements; investor communications may reference this Schedule 13G as passive ownership disclosure.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Haemonetics Corporation
(Name of Issuer)
Common stock, $.01 par value per share
(Title of Class of Securities)
02/24/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP Number(s):
1
Names of Reporting Persons
North Peak Capital Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,882,037.00
7
Sole Dispositive Power
488,458.00
8
Shared Dispositive Power
1,882,037.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,370,495.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.1 %
12
Type of Reporting Person (See Instructions)
IA, OO
Comment for Type of Reporting Person: The figures in Items 6, 8, and 9 include (1) 135,354 shares of Common stock, $.01 par value per share ("Common Stock") of Haemonetics Corporation (the "Issuer") held directly by North Peak Capital Partners, LP, (2) 993,566 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 651,061 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 102,056 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP.
The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025 filed with the U.S. Securities and Exchange Commission (the "Commission") on February 5, 2026.
SCHEDULE 13G
CUSIP Number(s):
1
Names of Reporting Persons
North Peak Capital GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,882,037.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,882,037.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,882,037.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.0 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The figures in Items 6, 8, and 9 include (1) 135,354 shares of Common Stock of the Issuer held directly by North Peak Capital Partners, LP, (2) 993,566 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 651,061 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 102,056 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP.
The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026.
SCHEDULE 13G
CUSIP Number(s):
1
Names of Reporting Persons
North Peak Capital Partners, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
135,354.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
135,354.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
135,354.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.3 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026.
SCHEDULE 13G
CUSIP Number(s):
1
Names of Reporting Persons
North Peak Capital Partners II, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
993,566.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
993,566.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
993,566.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.1 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026.
SCHEDULE 13G
CUSIP Number(s):
1
Names of Reporting Persons
North Peak Capital Alpha Fund, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
651,061.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
651,061.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
651,061.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.4 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026.
SCHEDULE 13G
CUSIP Number(s):
1
Names of Reporting Persons
North Peak Capital Ultra Fund, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
102,056.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
102,056.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
102,056.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.2 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026.
SCHEDULE 13G
CUSIP Number(s):
1
Names of Reporting Persons
Michael Kevin Kahan
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,882,037.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,882,037.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,882,037.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.0 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: The figures in Items 6, 8, and 9 include (1) 135,354 shares of Common Stock of the Issuer held directly by North Peak Capital Partners, LP, (2) 993,566 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 651,061 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 102,056 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP.
The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026.
SCHEDULE 13G
CUSIP Number(s):
1
Names of Reporting Persons
Jeremy Steven Kahan
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,882,037.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,882,037.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,882,037.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.0 %
12
Type of Reporting Person (See Instructions)
HC, CO
Comment for Type of Reporting Person: The figures in Items 6, 8, and 9 include (1) 135,354 shares of Common Stock of the Issuer held directly by North Peak Capital Partners, LP, (2) 993,566 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 651,061 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 102,056 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP.
The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Haemonetics Corporation
(b)
Address of issuer's principal executive offices:
125 SUMMER STREET, BOSTON, MA, 02110
Item 2.
(a)
Name of person filing:
This statement is jointly filed by and on behalf of each of North Peak Capital Management, LLC, a Delaware limited liability company ("North Peak Management"), North Peak Capital GP, LLC, a Delaware limited liability company ("North Peak GP"), North Peak Capital Partners, LP, a Delaware limited partnership ("Fund I"), North Peak Capital Partners II, LP, a Delaware limited partnership ("Fund II"), North Peak Capital Alpha Fund, LP, a Delaware limited partnership ("Alpha Fund"), North Peak Capital Ultra Fund, LP, a Delaware limited partnership ("Ultra Fund"), Jeremy S. Kahan and Michael K. Kahan (each, a "Reporting Person" and collectively, the "Reporting Persons"). North Peak Management is the investment manager of, and may be deemed to indirectly beneficially own securities owned by, each of Fund I, Fund II, Alpha Fund and Ultra Fund. North Peak Management is also an investment adviser to a separately managed account of an advisory client and may be deemed to beneficially own securities directly in such separately managed account, but North Peak Management does not have any voting authority with respect to any securities in such separately managed account. North Peak GP is the general partner of, and may be deemed to indirectly beneficially own securities owned by, each of Fund I, Fund II, Alpha Fund and Ultra Fund. Messrs. Kahan are the co-managers of, and each may be deemed to indirectly beneficially own securities beneficially owned by, each of North Peak Management and North Peak GP. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock held directly by the other Reporting Persons.
Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.
Each Reporting Person may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of each of the Reporting Persons is c/o North Peak Capital Management, LLC, 405 Lexington Avenue, Suite 5001, New York, NY 10174.
(c)
Citizenship:
See Item 4 on the cover page(s) hereto.
(d)
Title of class of securities:
Common stock, $.01 par value per share
(e)
CUSIP No.:
405024100
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
See Item 9 on the cover page(s) hereto.
(b)
Percent of class:
See Item 11 on the cover page(s) hereto.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See Item 5 on the cover page(s) hereto.
(ii) Shared power to vote or to direct the vote:
See Item 6 on the cover page(s) hereto.
(iii) Sole power to dispose or to direct the disposition of:
See Item 7 on the cover page(s) hereto.
(iv) Shared power to dispose or to direct the disposition of:
See Item 8 on the cover page(s) hereto.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
North Peak Capital Management, LLC
Signature:
/s/ Jeremy Kahan
Name/Title:
Jeremy Kahan/Managing Member
Date:
03/03/2026
North Peak Capital GP, LLC
Signature:
/s/ Jeremy Kahan
Name/Title:
Jeremy Kahan/Manager
Date:
03/03/2026
North Peak Capital Partners, LP
Signature:
/s/ Jeremy Kahan
Name/Title:
Jeremy Kahan/Manager of North Peak Capital GP, LLC, its General Partner
Date:
03/03/2026
North Peak Capital Partners II, LP
Signature:
/s/ Jeremy Kahan
Name/Title:
Jeremy Kahan/Manager of North Peak Capital GP, LLC, its General Partner
Date:
03/03/2026
North Peak Capital Alpha Fund, LP
Signature:
/s/ Jeremy Kahan
Name/Title:
Jeremy Kahan/Manager of North Peak Capital GP, LLC, its General Partner
Date:
03/03/2026
North Peak Capital Ultra Fund, LP
Signature:
/s/ Jeremy Kahan
Name/Title:
Jeremy Kahan/Manager of North Peak Capital GP, LLC, its General Partner
What stake does North Peak report in Haemonetics (HAE)?
North Peak reports beneficial ownership of 2,370,495 shares, equal to 5.1% of Haemonetics common stock. This percentage uses a share base of 46,471,350 shares outstanding as of January 30, 2026.
Which North Peak entities hold shares in HAE?
Holdings are split across multiple entities: North Peak Capital Partners II (993,566), Alpha Fund (651,061), Partners (135,354), and Ultra Fund (102,056). Aggregated reporting shows the group total of 2,370,495 shares.
Do Jeremy S. Kahan and Michael K. Kahan hold Haemonetics shares?
Yes. Each Kahan is a reporting person tied to 1,882,037 shares (shared power) through North Peak entities, as shown on the joint Schedule 13G filed for Haemonetics.
What voting or dispositive power is reported by North Peak?
The filing reports shared voting power and shared dispositive power for the group, with 1,882,037 shared votes recorded for North Peak GP and the Kahan reporting persons; sole voting/dispositive power is reported as 0.00 for several entries.
What date and share count were used to compute the percentages?
Percentages are based on 46,471,350 shares outstanding as of January 30, 2026, per the issuer's Form 10-Q for the period ended December 27, 2025 filed on February 5, 2026.
